Vertex CEO Jeffrey Leiden took his fight over CF drug prices to U.K. Prime Minister Theresa May, urging her to step in.
Cost-effectiveness watchdog ICER routinely reviews new drug prices, but now it's aiming to unveil price hikes on older meds.
Sanofi offered a confidential discount as part of a process to secure coverage for Dupixent in the U.K.
Patients in the U.K. won't have access to X-linked hypophosphatemia med Crysvita under a ruling by NICE.
After learning Aimovig's official price, ICER revised its work to conclude the migraine prevention drug is cost-effective when other options fail.
The U.S. cost-effectiveness watchdog suggests discounts of up to 77% on Vertex's cystic fibrosis drugs, but the company calls the process a "sham."
After a previous rejection and a discount offer, Roche's immunotherapy Tecentriq snagged an OK from England's influential cost-effectiveness watchdogs.
The cost-effectiveness gatekeeper figures Dupixent works—and offers an option for patients who really need one—but isn't sure it's worth the price.
Impax Laboratories will sell its manufacturing site in Taiwan to Bora Pharmaceuticals for $18.5 million and take a charge of up to $80 million.
Cost watchdogs in England and pharma don't always agree, but the sides are celebrating two new deals on Merck KGaA's Mavenclad and Roche's Perjeta.